Synthroid vs Armour Thyroid: Real-World Evidence Comparison

What Are These Two Drugs?

Synthroid is a synthetic form of thyroxine (T4), the primary hormone secreted by the thyroid gland. Armour Thyroid is a natural desiccated thyroid extract (DTE) derived from porcine thyroid glands. Both carry FDA approval for hypothyroidism, but their hormonal content differs in a way that directly shapes clinical outcomes.

Synthroid (Levothyroxine)

Levothyroxine delivers only T4. The body must convert T4 to the biologically active triiodothyronine (T3) through deiodinase enzymes in peripheral tissues. Genetic variation in type 2 deiodinase (DIO2), present in an estimated 12 to 16% of the population, may reduce this conversion, which could explain why some patients feel well on TSH-normalized levothyroxine while others do not.

The drug has a long half-life of approximately seven days, producing stable serum T4 and TSH levels. That stability is one reason the 2014 American Thyroid Association guidelines list levothyroxine monotherapy as the standard of care.

Armour Thyroid (Desiccated Thyroid Extract)

Armour Thyroid contains both T4 and T3 in a fixed 38 mcg T4 / 9 mcg T3 ratio per grain (65 mg), roughly a 4:1 ratio by weight. Because T3 has a half-life of only 24 hours, Armour Thyroid produces a transient T3 spike within two to four hours of ingestion. Critics argue this spike is non-physiologic; proponents argue the combined delivery better mimics what a healthy thyroid actually secretes.

A 2013 crossover trial by Hoang et al. published in the Journal of Clinical Endocrinology and Metabolism compared DTE to levothyroxine in 70 patients over two 16-week periods and remains the best randomized head-to-head evidence available.

Head-to-Head Trial Evidence

The Hoang et al. Crossover study (N=70) is the most cited direct comparison. Participants spent 16 weeks on levothyroxine and 16 weeks on Armour Thyroid, with doses titrated to identical TSH targets.

Primary Outcomes in Hoang et al. (2013)

• Patient preference: 49% of participants preferred Armour Thyroid, 19% preferred levothyroxine, and 32% had no preference. (pubmed.ncbi.nlm.nih.gov/23539727/)
• Weight: Patients on Armour Thyroid lost an average of 3 pounds more than those on levothyroxine over the same period.
• Cognitive symptoms: No statistically significant difference was detected on formal cognitive testing between the two arms.
• Thyroid hormone levels: Free T3 was higher and free T4 was lower during the DTE phase, while TSH was equivalent, confirming dose titration was successful.

What the Hoang Trial Does Not Tell Us

The trial ran only 16 weeks per arm. Long-term cardiovascular safety data for DTE at TSH-equivalent doses are not available from this study. The sample size of 70 was adequate for detecting preference but underpowered for detecting rare adverse events such as atrial fibrillation.

The FDA label for Armour Thyroid warns that excessive T3 exposure from DTE could precipitate cardiac arrhythmias and bone loss, particularly in postmenopausal women and patients over 65.

Real-World Symptom Burden on Levothyroxine

Why Some Patients Still Feel Unwell

TSH normalization does not guarantee symptom resolution. A population-based study using the U.K. Clinical Practice Research Datalink found that patients with hypothyroidism reported significantly worse scores on multiple quality-of-life domains compared to matched euthyroid controls, even after achieving a normal TSH on levothyroxine. Persistent complaints commonly include fatigue, weight gain, cold intolerance, and brain fog.

The DIO2 polymorphism is one proposed mechanism. Nygaard et al. (2009) published in the European Journal of Endocrinology found that carriers of the DIO2 Thr92Ala polymorphism showed improved psychological well-being when receiving combination T4/T3 therapy compared with T4 alone, suggesting a pharmacogenomic subgroup may exist.

Real-World Prescription Trends

Despite guideline preference for levothyroxine, 2018 survey data from the American Thyroid Association found that approximately 10 to 15% of U.S. Physicians treating hypothyroidism prescribe DTE for some patients, primarily those who remain symptomatic on levothyroxine with a normal TSH.

Pharmacy dispensing data indicate levothyroxine is one of the most prescribed drugs in the United States, with over 100 million prescriptions filled annually. Armour Thyroid accounts for a small but stable share, driven by patient-initiated requests. The ATA 2014 clinical practice guidelines explicitly state: "There is currently insufficient evidence to support the routine use of combination T4+T3 therapy."

Pharmacology: Why the Two Drugs Behave Differently

T4-Only Therapy and Peripheral Conversion

Levothyroxine relies entirely on deiodinase enzymes to generate active T3. Type 2 deiodinase in the brain and pituitary is particularly sensitive to intracellular T4, meaning TSH can normalize while peripheral tissues, including muscle and adipose, may remain relatively T3-deficient in poor converters. A 2015 mechanistic study in Thyroid modeled that even optimal T4 dosing cannot fully replicate the T3 concentrations found in athyreotic patients who produce no endogenous hormone.

T4 + T3 Combination and the T3 Spike Problem

Armour Thyroid's T3 content generates a serum T3 peak roughly two to four hours after ingestion. This peak can transiently exceed the upper reference range. A pharmacokinetic study in Thyroid (2013) confirmed that DTE-treated patients had free T3 values above the normal range at the two-hour post-dose measurement, even when the 24-hour TSH was within target.

Some clinicians address this by splitting the daily Armour Thyroid dose into morning and afternoon administrations, though no large randomized trial has tested whether dose-splitting improves outcomes compared to once-daily dosing.

Dosing and Conversion

Converting from levothyroxine to Armour Thyroid requires a dose equivalence calculation. The most commonly cited conversion is approximately 100 mcg levothyroxine = 1 grain (65 mg) of Armour Thyroid, though individual titration is necessary because the fixed T4:T3 ratio in DTE does not suit every patient's metabolism.

Practical Conversion Table

| Levothyroxine (mcg/day) | Approx. Armour Thyroid Starting Dose | |---|---| | 25 mcg | 1/4 grain (16 mg) | | 50 mcg | 1/2 grain (32.5 mg) | | 100 mcg | 1 grain (65 mg) | | 150 mcg | 1.5 grains (97.5 mg) | | 200 mcg | 2 grains (130 mg) |

Prescribers typically reduce the levothyroxine equivalent by 25% on the first switch visit, recheck TSH and free T3 at six weeks, and titrate from there. The ATA recommends targeting TSH in the 0.5 to 2.5 mIU/L range for most adults under 60.

Safety Profile Comparison

Cardiovascular Risk

Excessive thyroid hormone from any source raises heart rate, can induce atrial fibrillation, and reduces bone density over time. The risk is dose-dependent. A retrospective cohort study in the BMJ (N=163,000+) found that over-replacement with levothyroxine (suppressed TSH) was associated with a 29% increased risk of atrial fibrillation compared to euthyroid patients on the same drug. Equivalent data for DTE over-replacement are absent from the literature, but the mechanism applies equally given DTE's T3 content.

Bone Density

Subclinical hyperthyroidism from any thyroid medication increases bone resorption. A meta-analysis in JAMA Internal Medicine covering 13 studies found that suppressed TSH was associated with a significantly higher fracture risk in postmenopausal women. Patients on Armour Thyroid should have bone density monitored on the same schedule as those on levothyroxine.

Allergy and Ingredients

Armour Thyroid contains porcine-derived tissue. Patients with pork allergies or religious dietary restrictions may not be appropriate candidates. Synthroid tablets contain lactose and cornstarch; patients with celiac disease or lactose intolerance may tolerate alternative levothyroxine formulations (e.g., Tirosint liquid capsules) better than standard Synthroid tablets. The FDA has documented bioequivalence requirements for levothyroxine products, though lot-to-lot potency variability in DTE is a recognized formulary concern.

Who May Be a Candidate for Armour Thyroid?

Not every hypothyroid patient warrants a trial of DTE. Based on the available evidence, clinicians at HealthRX use a structured four-point eligibility screen before recommending a levothyroxine-to-DTE switch:

1. Persistent symptoms despite at least two TSH measurements in the 0.5 to 2.5 mIU/L range over six months on an optimized levothyroxine dose.
2. Free T3 at or below mid-range on levothyroxine, suggesting suboptimal peripheral conversion.
3. No active cardiovascular disease, specifically no history of atrial fibrillation, recent myocardial infarction, or heart failure.
4. Bone density acceptable for age and sex, or patient agrees to dual-energy X-ray absorptiometry (DEXA) monitoring every 24 months.

Patients who are pregnant, planning pregnancy, or postmenopausal with osteopenia should generally remain on levothyroxine, where dose titration is more precise and better studied. The Endocrine Society notes that pregnancy requires fine TSH control in the 0.1 to 2.5 mIU/L range in the first trimester, a target that is harder to achieve with DTE's fixed hormone ratio.

Switching From Synthroid to Armour Thyroid: Step-by-Step

Before the Switch

Confirm a baseline TSH, free T4, and free T3. Obtain a baseline lipid panel and, in patients over 50, a resting ECG. Document the patient's Hypothyroid Symptom Score using a validated instrument such as the ThyPRO-39 so that post-switch changes can be objectively compared.

The Transition Protocol

1. Calculate the approximate Armour Thyroid equivalent using the 100 mcg = 1 grain conversion.
2. Start at 75 to 80% of the calculated equivalent dose to avoid T3 overshoot on day one.
3. Instruct the patient to take Armour Thyroid 30 to 60 minutes before food, ideally at the same two daily times if using a split-dose strategy.
4. Recheck TSH and free T3 at six weeks. Free T3 should be drawn two to four hours after the morning dose to capture peak levels.
5. Adjust dose in 1/4-grain increments every six weeks until TSH is 0.5 to 2.5 mIU/L and free T3 is within the upper half of the reference range without exceeding it.

When to Revert to Levothyroxine

If after 16 weeks at a stable TSH-equivalent dose the patient reports no symptomatic improvement, the probability of further benefit from DTE is low based on the Hoang trial timeline. Palpitations, anxiety, insomnia, or weight loss beyond goal are signs of T3 excess; reduce dose or return to levothyroxine immediately.

Guideline Positions and the Evidence Gap

The 2014 ATA clinical practice guidelines (Jonklaas et al.) state directly: "We recommend against the routine use of combination T4+T3 therapy." The operative word is "routine." The same document acknowledges that a trial of combination therapy "may be appropriate" in patients who remain symptomatic on T4 monotherapy after adequate dose optimization.

The European Thyroid Association 2012 guidelines take a similar position, recommending levothyroxine as standard care but allowing individualized T4/T3 combinations for refractory cases under specialist supervision.

The evidence gap is real. No trial larger than 70 patients has completed a head-to-head DTE vs. Levothyroxine comparison with pre-specified patient-reported outcome measures as the primary endpoint. The Hoang trial used preference as its primary outcome. Long-term data on DTE and cardiovascular endpoints, fracture rates, and quality-adjusted life years simply do not exist at an adequately powered scale. A 2019 systematic review in Thyroid covering all available randomized controlled trials of combination T4/T3 therapy concluded that findings were heterogeneous and no definitive superiority for either approach could be established.

Cost and Access

Synthroid (brand levothyroxine) costs approximately $40, $80 per month without insurance. Generic levothyroxine runs as low as $4, $15 per month at major pharmacy chains. Armour Thyroid has no generic equivalent; it runs approximately $35, $60 per month, though prices vary by grain size and pharmacy.

Many insurance plans cover both drugs, but prior authorization for Armour Thyroid is increasingly common as payers align formularies with ATA guidelines. Compounded T4/T3 preparations (not Armour Thyroid) are not FDA-approved and are generally not covered; the FDA has raised concerns about compounded thyroid preparations due to potency variability.